NANOBIOTIX Announces Presentation of new Data From Phase 1 I

New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent

Related Keywords

University Of Chicago , Illinois , United States , Texas , Chapel Hill , North Carolina , Florida , Cambridge , Cambridgeshire , United Kingdom , New York , Paris , France General , France , Tampa , University Of North Carolina , Maryland , Arizona , Massachusetts , Baltimore , Chicago , American , Kedar Kirtane , Jessica Frakes , Shetal Patel , Siddharth Sheth , David Rolando , Aditya Joolori , Trevor Hackman , Omari Vivar , Paul Chang , Jiaxin Niu , Septimiu Murgu , Colette Shen , George Yang , Tanguy Seiwert , Jared Weiss , Jimmy Caudell , University Of Texas Md Anderson Cancer Center , Linkedin , Moffitt Cancer Center , Twitter , Given The Company , Drug Administration , Nasdaq , University Of North Carolina School Medicine , Banner Md Anderson Cancer Center , Euronext , Coordinating Investigator Colette Shen , American Society , Investigator Colette Shen , Pavel Tyan , Zhen Gooi , Sari Rosenberg , Laurent Levy , Sunday June , North Carolina School , Cancer Center , Hopkins Medicine , United States Food , Fast Track , Janssen Pharmaceutica , Euronext Paris , Nasdaq Global Select Market , New York City ,